Tempest Pivoted Into CAR-T And The Early Data Looks Good
Tempest's TPST-2003 hit 100% CR in 6 evaluable r/r multiple myeloma patients. ISCT 2026 update incoming.
Jeff Martin
TDP-43 Finally Has a Real Toolbox: Two ALS Programs, Two Modalities, One Protein
Two ALS programs, two modalities, one protein. AcuraStem's ASO and VectorY's vectorized antibody are starting to give the 97% of ALS patients without SOD1 mutations a real toolbox.
Tacalyx Lands €11M to Take Glycan-Targeted ADCs Out of the Curiosity Bin
Tacalyx pulls €11M seed extension to push glycan-targeted ADC TCX-201 toward 2027 CTA filing.
Hypervision Surgical’s £17M Round Bets on AI in the OR, Not the Lab
Hypervision Surgical pulls £17M Series A for an FDA-cleared hyperspectral imaging platform that uses AI to differentiate tumor, nerves, and blood vessels in real-time during surgery.
Theolytics Doses First Ovarian Patient with a Virus That Kills Both Tumor and Stroma
Theolytics doses first patient in OCTOPOD-IP for THEO-260, an oncolytic virus targeting both ovarian tumors and CAFs.
Coultreon Pulls $125M Series A From Galapagos’s Quiet 15-Year SIK Bench
Coultreon raises $125M Series A on 15 years of Galapagos SIK biology, advancing oral SIK3 inhibitor in immunology.
The In Vivo CAR-T Hype Train Has Left The Station. It Was A Crazy Month.
A roundup of the early-stage in vivo CAR-T signals we've covered this month, from preclinical to first-in-human.
TRex Bio Doses First Patient on a Treg-Expanding TNFR2 Agonist
TRex Bio doses first AD patient with TRB-061, a TNFR2 agonist that expands tissue-resident Tregs instead of suppressing inflammation.
Laguna Is Pumping Kids Full of Bacteria To Treat Pediatric Leukemia
Laguna lands FDA IND for LGNA-100, an engineered Listeria activating γδ T cells in pediatric leukemia post-HSCT.
EvolveImmune Triggers First $18M Milestone in AbbVie’s $1.4B Trispecific Bet
EvolveImmune triggers $18M milestone from AbbVie partnership advancing trispecific T cell engagers with CD2 costimulation.